Esmolol
Beta Blocking Agents, Selective
- Drug class
- Beta Blocking Agents, Selective
- Availability
- Prescription only
- Routes
- Intravenous
- Markets covered
- 2
- Products on record
- 9
Overview
Plain-language summary, compiled from the cited regulatory records
Esmolol is a medication classified as a selective beta-blocking agent [1]. It is approved for the short-term management of specific cardiovascular conditions. Esmolol hydrochloride injection is indicated for controlling the ventricular rate in cases of supraventricular tachycardia, including atrial fibrillation and atrial flutter [1]. It is also used to control heart rate in noncompensatory sinus tachycardia [1].
Additionally, esmolol hydrochloride injection is indicated for the control of tachycardia and hypertension that may occur around the time of surgical procedures [1]. This medication is available under various brand names.
There have been [null] adverse event reports for esmolol in the past 12 months [2].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 7 | May 1, 2026 |
| US United States | FDA | 2 | October 9, 2023 |
GBUnited Kingdom· MHRA
7 products
Uses
• Supraventricular tachycardia (except for pre-excitation syndromes) or non- compensatory sinus tachycardia Brevibloc is indicated for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other circumstances where short-term control of the ventricular rate with a short acting agent is desirable.
Brevibloc is also indicated for non-compensatory sinus tachycardia where, in the physician’s judgment the rapid heart rate requires specific intervention. • Tachycardia and hypertension occurring in the perioperative phase Treatment of tachycardia and hypertension that occur during induction of anesthesia and tracheal intubation, during surgery, on emergence from anesthesia, and in the postoperative period, when in the physician’s judgment such specific intervention is considered indicated.
2). Brevibloc is not intended for use in chronic settings.
USUnited States· FDA
2 products
Uses
1 Supraventricular Tachycardia or Noncompensatory Sinus Tachycardia Esmolol hydrochloride injection is indicated for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable.
Esmolol hydrochloride injection is also indicated in noncompensatory sinus tachycardia where, in the physician’s judgment, the rapid heart rate requires specific intervention. Esmolol hydrochloride injection is intended for short-term use.
2 Intraoperative and Postoperative Tachycardia and/or Hypertension Esmolol hydrochloride injection is indicated for the short-term treatment of tachycardia and hypertension that occur during induction and tracheal intubation, during surgery, on emergence from anesthesia and in the postoperative period, when in the physician’s judgment such specific intervention is considered indicated.
Drug interactions
Known interactions involving Esmolol. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 330. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL001160352 · revised June 6, 2025
- [2]FDA DailyMed · 017023a9-00f0-42… · revised June 23, 2023 [PDF]
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.